AU2015229103C9 - Antibody molecules to LAG-3 and uses thereof - Google Patents

Antibody molecules to LAG-3 and uses thereof Download PDF

Info

Publication number
AU2015229103C9
AU2015229103C9 AU2015229103A AU2015229103A AU2015229103C9 AU 2015229103 C9 AU2015229103 C9 AU 2015229103C9 AU 2015229103 A AU2015229103 A AU 2015229103A AU 2015229103 A AU2015229103 A AU 2015229103A AU 2015229103 C9 AU2015229103 C9 AU 2015229103C9
Authority
AU
Australia
Prior art keywords
seq
bap050
amino acid
acid sequence
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015229103A
Other languages
English (en)
Other versions
AU2015229103B2 (en
AU2015229103A1 (en
AU2015229103C1 (en
Inventor
Walter A. Blattler
Chrystelle BRIGNONE
Hwai Wen Chang
Gerhard Johann Frey
Jennifer Marie Mataraza
Catherine Anne SABATOS-PEYTON
Frederic Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Immutep SAS
Original Assignee
Novartis AG
Immutep SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52780053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015229103(C9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Immutep SAS filed Critical Novartis AG
Publication of AU2015229103A1 publication Critical patent/AU2015229103A1/en
Publication of AU2015229103B2 publication Critical patent/AU2015229103B2/en
Priority to AU2020256466A priority Critical patent/AU2020256466B2/en
Application granted granted Critical
Publication of AU2015229103C1 publication Critical patent/AU2015229103C1/en
Publication of AU2015229103C9 publication Critical patent/AU2015229103C9/en
Priority to AU2024204473A priority patent/AU2024204473A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015229103A 2014-03-14 2015-03-13 Antibody molecules to LAG-3 and uses thereof Active AU2015229103C9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020256466A AU2020256466B2 (en) 2014-03-14 2020-10-19 Antibody molecules to LAG-3 and uses thereof
AU2024204473A AU2024204473A1 (en) 2014-03-14 2024-06-28 Antibody molecules to LAG-3 and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461953536P 2014-03-14 2014-03-14
US61/953,536 2014-03-14
US201462059690P 2014-10-03 2014-10-03
US62/059,690 2014-10-03
US201462094889P 2014-12-19 2014-12-19
US62/094,889 2014-12-19
PCT/US2015/020474 WO2015138920A1 (en) 2014-03-14 2015-03-13 Antibody molecules to lag-3 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020256466A Division AU2020256466B2 (en) 2014-03-14 2020-10-19 Antibody molecules to LAG-3 and uses thereof

Publications (4)

Publication Number Publication Date
AU2015229103A1 AU2015229103A1 (en) 2016-08-04
AU2015229103B2 AU2015229103B2 (en) 2020-07-23
AU2015229103C1 AU2015229103C1 (en) 2020-10-22
AU2015229103C9 true AU2015229103C9 (en) 2020-11-26

Family

ID=52780053

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015229103A Active AU2015229103C9 (en) 2014-03-14 2015-03-13 Antibody molecules to LAG-3 and uses thereof
AU2020256466A Active AU2020256466B2 (en) 2014-03-14 2020-10-19 Antibody molecules to LAG-3 and uses thereof
AU2024204473A Pending AU2024204473A1 (en) 2014-03-14 2024-06-28 Antibody molecules to LAG-3 and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020256466A Active AU2020256466B2 (en) 2014-03-14 2020-10-19 Antibody molecules to LAG-3 and uses thereof
AU2024204473A Pending AU2024204473A1 (en) 2014-03-14 2024-06-28 Antibody molecules to LAG-3 and uses thereof

Country Status (36)

Country Link
US (5) US20150259420A1 (cg-RX-API-DMAC7.html)
EP (2) EP3116909B1 (cg-RX-API-DMAC7.html)
JP (4) JP6576962B2 (cg-RX-API-DMAC7.html)
KR (3) KR102442436B1 (cg-RX-API-DMAC7.html)
CN (2) CN113583129A (cg-RX-API-DMAC7.html)
AU (3) AU2015229103C9 (cg-RX-API-DMAC7.html)
BR (1) BR122024001145A2 (cg-RX-API-DMAC7.html)
CA (1) CA2936962C (cg-RX-API-DMAC7.html)
CL (2) CL2016002112A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160425A (cg-RX-API-DMAC7.html)
CU (1) CU24481B1 (cg-RX-API-DMAC7.html)
CY (1) CY1122510T1 (cg-RX-API-DMAC7.html)
DK (1) DK3116909T3 (cg-RX-API-DMAC7.html)
EA (1) EA201691765A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16081503A (cg-RX-API-DMAC7.html)
ES (1) ES2770684T3 (cg-RX-API-DMAC7.html)
GT (1) GT201600185A (cg-RX-API-DMAC7.html)
HR (1) HRP20192346T1 (cg-RX-API-DMAC7.html)
HU (1) HUE048531T2 (cg-RX-API-DMAC7.html)
IL (3) IL246781B (cg-RX-API-DMAC7.html)
JO (1) JOP20150048B1 (cg-RX-API-DMAC7.html)
LT (1) LT3116909T (cg-RX-API-DMAC7.html)
ME (1) ME03558B (cg-RX-API-DMAC7.html)
MX (2) MX389741B (cg-RX-API-DMAC7.html)
MY (1) MY187246A (cg-RX-API-DMAC7.html)
PE (1) PE20170071A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501545B1 (cg-RX-API-DMAC7.html)
PL (1) PL3116909T3 (cg-RX-API-DMAC7.html)
PT (1) PT3116909T (cg-RX-API-DMAC7.html)
RS (1) RS59853B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201605951YA (cg-RX-API-DMAC7.html)
SI (1) SI3116909T1 (cg-RX-API-DMAC7.html)
TW (4) TWI777174B (cg-RX-API-DMAC7.html)
UY (1) UY36032A (cg-RX-API-DMAC7.html)
WO (1) WO2015138920A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201604740B (cg-RX-API-DMAC7.html)

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
AU2015240595B2 (en) 2014-04-03 2020-02-27 Igm Biosciences, Inc. Modified J-chain
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CA2972048C (en) * 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2978324A1 (en) 2015-03-04 2016-09-09 Igm Biosciences, Inc. Cd20 binding molecules and uses thereof
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
US11060150B2 (en) * 2015-03-17 2021-07-13 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating cancer
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
PT3298021T (pt) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
HRP20201031T1 (hr) 2015-05-29 2020-10-16 Agenus Inc. Anti-ctla-4 protutijela i postupci njihove upotrebe
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) * 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
ES2898958T3 (es) 2015-07-30 2022-03-09 Macrogenics Inc Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
RU2021133819A (ru) * 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
SI3355913T1 (sl) 2015-09-30 2025-01-31 Igm Biosciences, Inc. Vezalne molekule z modificirano j-verigo
ES2819870T3 (es) * 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
IL257110B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Bispecific antibodies specific against pd1 and tim3
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EP3973988A1 (en) 2015-11-04 2022-03-30 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
US20190330336A1 (en) * 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
KR20180086502A (ko) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017123643A1 (en) * 2016-01-11 2017-07-20 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
AU2017228474C1 (en) 2016-03-04 2024-03-28 Abmuno Therapeutics Llc Antibodies to TIGIT
US20200281973A1 (en) 2016-03-04 2020-09-10 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3225253A1 (en) 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
IL262892B2 (en) * 2016-05-18 2024-04-01 Boehringer Ingelheim Int Anti pd-1 and anti-lag3 antibodies for cancer treatment
RU2018142573A (ru) * 2016-06-20 2020-07-21 Ф-Стар Бета Лимитед Партнеры по связыванию lag-3
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
SI3472207T1 (sl) * 2016-06-20 2021-04-30 F-Star Delta Limited Vezavne molekule, ki vežejo PD-L1 in LAG-3
PT3476399T (pt) 2016-06-23 2022-05-31 Jiangsu Hengrui Medicine Co Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EA039718B1 (ru) * 2016-07-21 2022-03-03 Регенерон Фармасьютикалз, Инк. Антитела к lag3 и их применения
US20180043011A1 (en) * 2016-08-10 2018-02-15 Wisconsin Alumni Research Foundation PI3-Kinase Inhibition and LAG-3 Checkpoint blockade as a Combination Therapy for Cancer
CN109689870B (zh) * 2016-09-08 2022-11-29 第一三共株式会社 用于治疗自身免疫疾病的抗体
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3526255A2 (en) * 2016-10-13 2019-08-21 Symphogen A/S Anti-lag-3 antibodies and compositions
EP3534950A4 (en) 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Tesaro, Inc. anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
UY37463A (es) 2016-11-02 2018-05-31 Glaxosmithkline Ip No 2 Ltd Proteínas de unión
ES3008937T3 (en) 2016-11-04 2025-03-25 Aximmune Inc Beta-alethine in combination with immune modulators and uses thereof
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190104529A (ko) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포의 조절 방법
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
CA3049536A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
JP6929951B2 (ja) * 2017-02-22 2021-09-01 アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｌａｇ−３抗体およびその使用
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
CN114949228A (zh) 2017-04-05 2022-08-30 勃林格殷格翰国际有限公司 抗癌组合疗法
IL268620B2 (en) * 2017-04-05 2024-04-01 Hoffmann La Roche Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
WO2018185232A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
EP4516809A3 (en) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
SG11201909395TA (en) * 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
CN110691795A (zh) * 2017-05-30 2020-01-14 百时美施贵宝公司 包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
CA3065929A1 (en) 2017-06-01 2018-12-06 Michael Wayne SAVILLE Bispecific antibodies that bind cd123 and cd3
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
KR20200037250A (ko) * 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
IL319798A (en) * 2017-07-20 2025-05-01 Novartis Ag ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型
EP3675898A4 (en) 2017-08-30 2021-09-01 Phanes Therapeutics, Inc. ANTI-LAG-3 ANTIBODIES AND THEIR USES
JP2020532537A (ja) 2017-08-31 2020-11-12 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
KR102818021B1 (ko) 2017-10-05 2025-06-10 다이이찌 산쿄 가부시키가이샤 세포 상해성 t 세포 고갈용 조성물
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3973973A1 (en) * 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN112272563A (zh) * 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
MX2020005478A (es) 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida y usos de los mismos.
JP6751212B2 (ja) * 2017-11-29 2020-09-02 大鵬薬品工業株式会社 抗腫瘍剤
AU2018375738A1 (en) 2017-11-30 2020-06-11 Novartis Ag BCMA-targeting chimeric antigen receptor, and uses thereof
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
CN111741976B (zh) 2017-12-19 2024-09-17 英沃克斯制药有限公司 包括pd-l1抗原结合位点的fc结合片段
EP3714901A4 (en) 2017-12-22 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019152574A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3758751A4 (en) 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
TWI833738B (zh) * 2018-03-20 2024-03-01 中國大陸商上海藥明生物技術有限公司 新型抗lag-3抗體多肽
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
EP3774834A1 (en) 2018-03-27 2021-02-17 Boehringer Ingelheim International GmbH Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
EP3774833A1 (en) 2018-03-27 2021-02-17 Boehringer Ingelheim International GmbH Modified cyclic dinucleotide compounds
CN111886254B (zh) * 2018-03-30 2023-12-08 南京传奇生物科技有限公司 针对lag-3的单结构域抗体及其用途
EP3778639A4 (en) * 2018-04-02 2021-06-09 Mab-Venture Biopharm Co., Ltd. LYMPHOCYTE ANTIGEN-3 (LAG-3) BINDING ANTIBODY AND ITS USES
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
CN112074541A (zh) * 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019276656A1 (en) 2018-06-01 2021-01-07 Novartis Ag Dosing of a bispecific antibody that bind CD123 and CD3
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
KR102250234B1 (ko) * 2018-06-29 2021-05-10 주식회사 와이바이오로직스 Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도
BR112020026947B1 (pt) 2018-07-10 2022-11-22 Novartis Ag Derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, e composição farmacêutica
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
MX2021003539A (es) 2018-09-26 2021-05-27 Astellas Pharma Inc Terapia contra el cancer en donde el virus vaccinia oncolitico e inhibidor de punto de control inmunitario se usan en combinacion, y composicion farmaceutica y medicamento de combinacion usado en ella.
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
TW202021981A (zh) 2018-11-01 2020-06-16 美商奇諾治療有限公司 G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
EP3886875B1 (en) 2018-11-30 2024-05-08 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
EP3890749B1 (en) 2018-12-04 2025-10-29 Sumitomo Pharma America, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
CA3119584A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
CA3119582A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1.beta. binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
JOP20210159A1 (ar) 2018-12-21 2023-01-30 Novartis Ag أجسام مضادة لـ pmel17 ومترافقات منها
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
MA54863A (fr) 2019-01-29 2021-12-08 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CA3133460A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
EP3946619A1 (en) 2019-03-26 2022-02-09 The Regents Of The University Of Michigan Small molecule degraders of stat3
EP3947403A1 (en) 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
EP3958900A4 (en) * 2019-04-26 2023-01-25 WuXi Biologics Ireland Limited BISPECIFIC ANTIBODIES AGAINST PD-1 AND LAG-3
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020241749A1 (ja) * 2019-05-29 2020-12-03 大鵬薬品工業株式会社 スルホンアミド化合物と免疫調節剤を用いるがん併用療法
CN112010972B (zh) * 2019-05-31 2023-01-10 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
US20220220204A1 (en) * 2019-06-12 2022-07-14 Nanjing GenScript Biotech Co., Ltd. Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof
AU2020291464A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
WO2020252336A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
KR20220038356A (ko) * 2019-06-26 2022-03-28 아뮤닉스 파마슈티컬스, 인크. Egfr 항원 결합 단편 및 이를 포함하는 조성물
JP2022538284A (ja) 2019-06-27 2022-09-01 ザ ジョージ ワシントン ユニバーシティ， ア コングレッショナリー チャータード ノット－フォー－プロフィット コーポレイション Ｈｄａｃ６活性化マクロファージ、その組成物および使用
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
CN114641337A (zh) 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CN115023267A (zh) 2019-09-19 2022-09-06 密歇根大学董事会 螺环雄激素受体蛋白质降解剂
CN112552411B (zh) * 2019-09-26 2022-07-29 无锡药明生物技术股份有限公司 新型抗pd-l1/抗lag-3双特异性抗体及其用途
AU2020358979A1 (en) 2019-10-03 2022-04-21 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
CN115942973A (zh) 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
TW202146452A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
CN114605544B (zh) * 2020-06-05 2023-08-01 北京天广实生物技术股份有限公司 Lag3抗体及其用途
PE20230839A1 (es) 2020-06-22 2023-05-19 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
KR20230058442A (ko) 2020-08-28 2023-05-03 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 lag-3 길항제 요법
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
CN116601140A (zh) 2020-10-02 2023-08-15 羿尊生物医药股份有限公司 用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途
JP2023548051A (ja) 2020-10-23 2023-11-15 ブリストル－マイヤーズ スクイブ カンパニー 肺がんのためのｌａｇ－３アンタゴニスト療法
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN116514971B (zh) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
EP4566674A3 (en) 2020-12-28 2025-08-06 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
US20240384350A1 (en) 2021-01-29 2024-11-21 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022253474A1 (en) 2021-04-08 2023-11-16 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
MX2023012277A (es) 2021-04-16 2023-12-07 Novartis Ag Conjugados anticuerpo-fármaco y métodos para fabricar los mismos.
US20220347282A1 (en) * 2021-04-28 2022-11-03 Wisconsin Alumni Research Foundation Anti-tumor dna vaccine with pd-1 and lag-3 pathway blockade
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
CN115611983A (zh) 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
KR20240099362A (ko) 2021-10-29 2024-06-28 브리스톨-마이어스 스큅 컴퍼니 혈액암에 대한 lag-3 길항제 요법
TW202334218A (zh) * 2021-11-01 2023-09-01 中國大陸商科望（蘇州）生物醫藥科技有限公司 新型抗ｌａｇ３抗體
JP2025503962A (ja) 2022-01-26 2025-02-06 ブリストル－マイヤーズ スクイブ カンパニー 肝細胞がんのための併用療法
US20250179174A1 (en) 2022-02-25 2025-06-05 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
JP2023140319A (ja) 2022-03-22 2023-10-04 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US20250332252A1 (en) 2022-06-02 2025-10-30 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
KR20250001490A (ko) * 2023-06-28 2025-01-07 주식회사 니오바이오파마슈티컬스 항-lag-3 항체, 항원 결합성 단편 및 이들의 용도
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004008218A1 (en) * 2002-07-10 2004-01-22 Infm Istituto Nazionale Per La Fisica Della Materia Optical microscope able to operate a rapid three dimensional modulation of the position of the observation point

Family Cites Families (526)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3884470T2 (de) 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2636953B1 (fr) 1988-09-26 1990-12-14 Roussy Inst Gustave Nouveaux polypeptides produits par des lymphocytes humains, genes codant pour ces polypeptides et applications pharmaceutiques et biologiques
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
ATE338134T1 (de) 1991-02-08 2006-09-15 Aventis Pharma Sa Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen
EP0528007A1 (fr) 1991-02-12 1993-02-24 Roussel Uclaf SEQUENCES NUCLEOTIDIQUES CODANT POUR DES REGIONS VARIABLES DE CHAINES $g(b) DES RECEPTEURS DES LYMPHOCYTES T HUMAINS, SEGMENTS PEPTIDIQUES CORRESPONDANTS ET LES APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5910573A (en) 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
KR100257466B1 (ko) 1994-05-06 2000-07-01 레지날드 쇼트버그 에스. 안토니우스-소도 Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DE69633175T2 (de) 1995-05-23 2005-08-11 Morphosys Ag Multimere proteine
WO1997003695A1 (en) * 1995-07-21 1997-02-06 Applied Research Systems Ars Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
JP2000508892A (ja) 1996-04-04 2000-07-18 ユニリーバー・ナームローゼ・ベンノートシャープ 多価および多特異的抗原結合タンパク
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
DE69735502T2 (de) 1996-11-28 2006-12-14 Applied Research Systems Ars Holding N.V. Mutanten des lag-3 proteins, ihre expression und verwendung
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
SI1325932T1 (cg-RX-API-DMAC7.html) 1997-04-07 2005-08-31 Genentech Inc
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU1102399A (en) 1997-10-21 1999-05-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
WO1999037791A1 (en) 1998-01-23 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Multipurpose antibody derivatives
EP1053321A1 (en) 1998-02-09 2000-11-22 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
WO1999052552A1 (en) 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
FR2794025A1 (fr) 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
JP2004523205A (ja) 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20020107363A1 (en) 2000-09-20 2002-08-08 Amgen, Inc. B7-Like molecules and uses thereof
EP2351838A1 (en) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7414171B2 (en) 2000-11-15 2008-08-19 Ono Pharmaceutical Co., Ltd. PD-1-lacking mouse and use thereof
JP2002194491A (ja) 2000-12-27 2002-07-10 Daido Steel Co Ltd ばね用鋼材
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1277843C (zh) 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP1383912A4 (en) 2001-04-02 2007-11-28 Wyeth Corp PD-1, B7-4 RECEPTOR, AND ITS USES
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US6727072B2 (en) 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US6592849B2 (en) 2001-06-21 2003-07-15 Colgate Palmolive Company Chewing gum to control malodorous breath
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
JP4572276B2 (ja) 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
JP2003029846A (ja) 2001-07-11 2003-01-31 Sanyo Electric Co Ltd 流量調整器および流量調整器を備えた飲料供給装置
EP1445264B1 (en) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Substance specific to pd-1
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
ES2336433T3 (es) 2001-09-19 2010-04-13 Alexion Pharmaceuticals, Inc. Moldes modififcados mediante ingenieria genetica y su uso en amplificacion de cebador unico.
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CN1582150B (zh) 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
AU2002357072A1 (en) 2001-12-07 2003-06-23 Centocor, Inc. Pseudo-antibody constructs
EP4091631A1 (en) 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. A tim-3 binding molecule for use in the treatment of a disease
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2345885T3 (es) 2002-11-15 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer.
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
EP1611112B1 (en) 2003-02-11 2012-08-22 Vernalis (Cambridge) Limited Isoxazole compounds as inhibitors of heat shock proteins
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
EP1897548B2 (en) 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
EP1618181B1 (en) 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
AU2004252170B2 (en) 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
KR20060089732A (ko) 2003-10-03 2006-08-09 브라이엄 앤드 위민즈 하스피틀 Ｔｉｍ-3 리간드 및 그의 방법
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EP1682103A1 (en) 2003-10-27 2006-07-26 Novartis AG Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
US20050276756A1 (en) 2004-03-24 2005-12-15 Hoo William S Compositions as adjuvants to improve immune responses to vaccines and methods of use
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CA2572098C (en) 2004-06-30 2015-01-27 Mayo Foundation For Medical Education And Research B7-dc binding antibody
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
KR20070038556A (ko) 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
MX2007003533A (es) 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 and PD-1 in the treatment of renal cell carcinoma
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
AU2006232920B2 (en) 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
MX349137B (es) 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
JP4557003B2 (ja) 2005-07-01 2010-10-06 株式会社村田製作所 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1757622B1 (en) 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008010561A (es) 2006-02-15 2009-03-02 Imclone Systems Inc Anticuerpos funcionales.
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
EP2027153B1 (en) 2006-05-25 2014-04-30 Bayer Intellectual Property GmbH Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
US20090241426A1 (en) 2006-07-14 2009-10-01 Pilkington North America, Inc. Vertical drop vehicle slider assembly
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
AU2007286808B2 (en) 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
DK3284825T3 (da) 2006-11-02 2021-05-25 Biomolecular Holdings Llc Fremgangsmåder til at fremstille hybride polypeptider med bevægelige dele
WO2008060617A2 (en) 2006-11-15 2008-05-22 The Brigham And Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
AU2007323725B2 (en) 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2008067283A2 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2008073687A2 (en) 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
US8153595B2 (en) 2007-07-13 2012-04-10 The Johns Hopkins University B7-DC variants immunogenic compositions and methods of use thereof
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CA2694488A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EA023031B1 (ru) 2007-11-30 2016-04-29 Глаксо Груп Лимитед Антиген-связывающая конструкция и ее применение
AR069803A1 (es) 2007-12-19 2010-02-17 Genentech Inc 5- anilinoimiazopiridinas y metodos de uso
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
HUE050958T2 (hu) 2008-01-15 2021-01-28 Univ Leland Stanford Junior Akut mieloid leukémia õssejtek markerei
US20110059106A1 (en) 2008-01-29 2011-03-10 Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
US8709715B2 (en) 2008-03-26 2014-04-29 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
JP5351254B2 (ja) 2008-05-23 2013-11-27 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8575427B2 (en) 2008-08-12 2013-11-05 The United States Of America As Represented By The Secretary Of Agriculture Chorismate mutase gene from the potato cyst nematode Globodera rostochiensis
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102753193A (zh) 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light靶向分子及其用途
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
CN102227221A (zh) 2008-11-28 2011-10-26 诺瓦提斯公司 包含hsp90抑制剂和mtor抑制剂的药物组合
JP2012510821A (ja) 2008-12-04 2012-05-17 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
JP5569946B2 (ja) 2009-01-26 2014-08-13 国立大学法人 岡山大学 免疫抑制剤および自己免疫疾患の予防および治療剤
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
WO2010102278A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
EP2412825B8 (en) 2009-03-24 2018-01-10 Riken Leukemia stem cell markers
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
LT2990421T (lt) 2009-04-30 2018-04-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti-ceacam1 antikūnai ir jų panaudojimo būdai
MX2011011669A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las misma.
BRPI1012195A2 (pt) 2009-05-01 2018-04-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
DK2769737T3 (en) 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IN2012DN01920A (cg-RX-API-DMAC7.html) 2009-09-03 2015-07-24 Schering Corp
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
AU2010303149B2 (en) 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
WO2011100841A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
SG185502A1 (en) 2010-05-14 2012-12-28 Abbvie Inc Il-1 binding proteins
JP6158511B2 (ja) 2010-06-11 2017-07-05 協和発酵キリン株式会社 抗ｔｉｍ−３抗体
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500333A1 (en) 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
BR112013010857A2 (pt) 2010-11-02 2016-09-13 Abbott Laboratoires imonoglubulinas de duplo domínio variável e usos das mesmas
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP6014596B2 (ja) 2010-11-09 2016-10-25 メディミューン，エルエルシー 均一コンジュゲーションのための抗体足場
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
US8814630B2 (en) 2011-01-04 2014-08-26 Carl T. Rittberger PVC beehive
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
PT3357511T (pt) 2011-06-30 2020-07-23 Genzyme Corp Inibidores da ativação de células t
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013043647A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013060867A2 (en) 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
EP3536710B1 (en) * 2011-11-16 2025-10-29 Boehringer Ingelheim International GmbH Anti il-36r antibodies
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
CA2892371C (en) 2011-12-01 2021-01-19 The Brigham And Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
CN102492038B (zh) 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
PE20210667A1 (es) 2012-05-15 2021-04-05 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
AU2013261129B2 (en) 2012-05-15 2016-05-12 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
EA201492007A1 (ru) 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104508149A (zh) 2012-07-27 2015-04-08 诺华股份有限公司 对jak/stat抑制剂治疗响应的预测
EP2879498A4 (en) 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
EP2879709B1 (en) 2012-07-31 2020-01-08 The Brigham and Women's Hospital, Inc. Modulation of the immune response
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP2904011B1 (en) 2012-10-02 2017-08-23 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
CN104994873B (zh) 2012-10-04 2017-12-22 达纳－法伯癌症研究所公司 人单克隆抗‑pd‑l1抗体和使用方法
AU2013343425A1 (en) 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
JP2016501221A (ja) 2012-11-28 2016-01-18 ノバルティス アーゲー 併用療法
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
IL240838B (en) 2013-03-15 2022-09-01 Glaxosmithkline Ip Dev Ltd Anti-3–lag binding proteins
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
CN103242448B (zh) 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
BR112015028326A8 (pt) 2013-06-03 2018-01-23 Novartis Ag combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
MX384142B (es) 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
EP3035964B1 (en) 2013-08-20 2020-09-23 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
KR102661249B1 (ko) 2013-09-11 2024-04-25 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
US10081681B2 (en) * 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP4285928A3 (en) 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
WO2015088847A1 (en) 2013-12-11 2015-06-18 Glaxosmithkline Llc Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015109124A2 (en) 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
RS62788B1 (sr) 2014-01-28 2022-02-28 Bristol Myers Squibb Co Anti-lag-3 antitela za lečenje hematoloških maligniteta
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SG11201606428UA (en) 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
WO2015120198A1 (en) 2014-02-05 2015-08-13 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
DK3105246T3 (da) 2014-02-10 2021-06-14 Merck Patent Gmbh Målrettet TGF-beta-inhibering
US20170088626A1 (en) 2014-03-05 2017-03-30 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
ES2753360T3 (es) 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
IL251464B2 (en) 2014-10-29 2023-03-01 Five Prime Therapeutics Inc Combination therapy for cancer
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE059218T2 (hu) * 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CN108136003A (zh) 2015-07-29 2018-06-08 诺华股份有限公司 抗pd-1和抗m-csf抗体在癌症治疗中的联合应用
ES2878188T3 (es) * 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
RU2018105846A (ru) 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
US20180222982A1 (en) * 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) * 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
RS59688B1 (sr) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN108430503A (zh) * 2015-10-28 2018-08-21 艾杜罗生物科技公司 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法
BR112018010211A2 (pt) 2015-12-07 2019-02-05 Merck Patent Gmbh formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP4643874A2 (en) * 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
IL260218B2 (en) * 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
WO2017189433A1 (en) 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018009466A1 (en) * 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN110214150A (zh) * 2016-07-28 2019-09-06 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
CA3066054A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
CN110785187B (zh) * 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
US20200223924A1 (en) * 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
IL319798A (en) * 2017-07-20 2025-05-01 Novartis Ag ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
MX2020004756A (es) * 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
CN109970856B (zh) * 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3119584A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
TW202124443A (zh) 2019-09-16 2021-07-01 瑞士商諾華公司 高親和力的、配位基阻斷性、人源化的抗T細胞免疫球蛋白結構域和黏蛋白結構域3(TIM-3)IgG4抗體用於治療骨髓纖維化之用途
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004008218A1 (en) * 2002-07-10 2004-01-22 Infm Istituto Nazionale Per La Fisica Della Materia Optical microscope able to operate a rapid three dimensional modulation of the position of the observation point

Also Published As

Publication number Publication date
TWI852057B (zh) 2024-08-11
CA2936962C (en) 2024-03-05
CY1122510T1 (el) 2021-01-27
MX389741B (es) 2025-03-20
KR20160134668A (ko) 2016-11-23
LT3116909T (lt) 2020-02-10
CN106103484A (zh) 2016-11-09
JP7030750B2 (ja) 2022-03-07
TW202321306A (zh) 2023-06-01
KR20240110004A (ko) 2024-07-12
CR20160425A (es) 2017-05-26
US20170210804A1 (en) 2017-07-27
CU24481B1 (es) 2020-03-04
GT201600185A (es) 2018-11-27
WO2015138920A1 (en) 2015-09-17
NZ722091A (en) 2024-04-26
EP3116909B1 (en) 2019-11-13
SI3116909T1 (sl) 2020-03-31
TWI777174B (zh) 2022-09-11
KR102442436B1 (ko) 2022-09-15
IL272488B (en) 2021-12-01
JP2017516489A (ja) 2017-06-22
SG11201605951YA (en) 2016-10-28
JP6576962B2 (ja) 2019-09-18
US10711060B2 (en) 2020-07-14
CN106103484B (zh) 2021-08-20
AU2020256466A1 (en) 2020-11-12
KR20220126813A (ko) 2022-09-16
ECSP16081503A (es) 2018-09-30
ME03558B (me) 2020-07-20
MX2022001043A (es) 2022-02-10
HUE048531T2 (hu) 2020-07-28
US20180086830A1 (en) 2018-03-29
TW202033561A (zh) 2020-09-16
ZA201604740B (en) 2022-12-21
CL2016002112A1 (es) 2017-06-09
JP2020005645A (ja) 2020-01-16
JP2024063093A (ja) 2024-05-10
AU2020256466B2 (en) 2024-03-28
AU2015229103B2 (en) 2020-07-23
IL246781A0 (en) 2016-08-31
EA201691765A1 (ru) 2016-12-30
AU2015229103A1 (en) 2016-08-04
MX2016011993A (es) 2016-12-09
BR122024001145A2 (pt) 2024-02-27
AU2024204473A1 (en) 2024-08-15
CN113583129A (zh) 2021-11-02
EP3660050A1 (en) 2020-06-03
PT3116909T (pt) 2020-01-30
PE20170071A1 (es) 2017-03-17
RS59853B1 (sr) 2020-02-28
US20150259420A1 (en) 2015-09-17
US20250382365A1 (en) 2025-12-18
TWI898718B (zh) 2025-09-21
TW202517678A (zh) 2025-05-01
HRP20192346T1 (hr) 2020-03-20
BR112016018408A2 (pt) 2017-12-26
PH12016501545B1 (en) 2023-12-06
UY36032A (es) 2015-10-30
TW201540727A (zh) 2015-11-01
MY187246A (en) 2021-09-14
IL272488A (en) 2020-03-31
CA2936962A1 (en) 2015-09-17
EP3116909A1 (en) 2017-01-18
US12252535B2 (en) 2025-03-18
AU2015229103C1 (en) 2020-10-22
US20210009687A1 (en) 2021-01-14
ES2770684T3 (es) 2020-07-02
DK3116909T3 (da) 2020-01-20
PL3116909T3 (pl) 2020-05-18
US9908936B2 (en) 2018-03-06
CL2018002694A1 (es) 2018-11-23
TWI697500B (zh) 2020-07-01
IL288012A (en) 2022-01-01
JP2022084616A (ja) 2022-06-07
PH12016501545A1 (en) 2016-09-14
JOP20150048B1 (ar) 2021-08-17
IL246781B (en) 2020-03-31

Similar Documents

Publication Publication Date Title
AU2020256466B2 (en) Antibody molecules to LAG-3 and uses thereof
US20250066479A1 (en) Antibody molecules to pd-1 and uses thereof
AU2015333687B2 (en) Antibody molecules to PD-L1 and uses thereof
HK40007040A (en) Antibody molecules to pd-1 and uses thereof
HK1225747A1 (en) Antibody molecules to pd-1 and uses thereof
HK1229355A1 (en) Antibody molecules to lag-3 and uses thereof

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 JUL 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 JUL 2020

FGA Letters patent sealed or granted (standard patent)
SREP Specification republished